CD19 and COVID-19: Hypogammaglobulinemia, a well-known side effect of cytotoxic chemotherapy, blinatumomab treatment, and anti-CD19 CAR-T cell therapy, is a risk factor for severe and prolonged COVID-19 [40,41].